PL3797107T3 - Heteroskondensowane związki pirydonów oraz ich zastosowanie jako inhibitory idh - Google Patents

Heteroskondensowane związki pirydonów oraz ich zastosowanie jako inhibitory idh

Info

Publication number
PL3797107T3
PL3797107T3 PL19726338.7T PL19726338T PL3797107T3 PL 3797107 T3 PL3797107 T3 PL 3797107T3 PL 19726338 T PL19726338 T PL 19726338T PL 3797107 T3 PL3797107 T3 PL 3797107T3
Authority
PL
Poland
Prior art keywords
heterocondensed
pyridone compounds
idh inhibitors
idh
inhibitors
Prior art date
Application number
PL19726338.7T
Other languages
English (en)
Inventor
Elena Casale
Francesco Casuscelli
Teresa Disingrini
Paola Magnaghi
Beatrice Malgesini
Ilaria MOTTO
Stefano Nuvoloni
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Publication of PL3797107T3 publication Critical patent/PL3797107T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL19726338.7T 2018-05-21 2019-05-16 Heteroskondensowane związki pirydonów oraz ich zastosowanie jako inhibitory idh PL3797107T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18173430 2018-05-21
PCT/EP2019/062605 WO2019224096A1 (en) 2018-05-21 2019-05-16 Heterocondensed pyridones compounds and their use as idh inhibitors

Publications (1)

Publication Number Publication Date
PL3797107T3 true PL3797107T3 (pl) 2022-12-05

Family

ID=62222436

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19726338.7T PL3797107T3 (pl) 2018-05-21 2019-05-16 Heteroskondensowane związki pirydonów oraz ich zastosowanie jako inhibitory idh

Country Status (16)

Country Link
US (1) US20210206759A1 (pl)
EP (1) EP3797107B1 (pl)
JP (1) JP7304896B2 (pl)
KR (1) KR20210013154A (pl)
CN (1) CN112469719B (pl)
AU (1) AU2019273599B2 (pl)
BR (1) BR112020023736A2 (pl)
CA (1) CA3100448A1 (pl)
DK (1) DK3797107T3 (pl)
EA (1) EA202092767A1 (pl)
ES (1) ES2929406T3 (pl)
HU (1) HUE060654T2 (pl)
MX (1) MX2020012499A (pl)
PL (1) PL3797107T3 (pl)
SG (1) SG11202011366SA (pl)
WO (1) WO2019224096A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038700A (zh) * 2019-11-08 2022-09-09 内尔维亚诺医疗科学公司 偕二取代的杂环化合物及其作为idh抑制剂的用途
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
CN115768775A (zh) * 2020-06-28 2023-03-07 微境生物医药科技(上海)有限公司 Idh突变体抑制剂及其用途
CN114685487B (zh) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2023178130A1 (en) * 2022-03-16 2023-09-21 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509805A (ja) * 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン
CZ20022521A3 (cs) * 2000-01-27 2003-02-12 Warner-Lambert Company Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění
JP2004083587A (ja) * 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
DK1685131T3 (da) 2003-11-13 2007-07-09 Hoffmann La Roche Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
BRPI0617159B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
AU2007284562B2 (en) * 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AP2015008707A0 (en) 2013-03-14 2015-09-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
EP3328866B1 (en) 2015-07-27 2019-10-30 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors

Also Published As

Publication number Publication date
JP7304896B2 (ja) 2023-07-07
MX2020012499A (es) 2021-02-15
BR112020023736A2 (pt) 2021-02-09
AU2019273599A1 (en) 2021-01-14
ES2929406T3 (es) 2022-11-29
DK3797107T3 (da) 2022-11-07
CN112469719A (zh) 2021-03-09
KR20210013154A (ko) 2021-02-03
JP2021525247A (ja) 2021-09-24
EP3797107B1 (en) 2022-08-10
EP3797107A1 (en) 2021-03-31
AU2019273599A2 (en) 2021-01-21
US20210206759A1 (en) 2021-07-08
AU2019273599B2 (en) 2023-12-14
EA202092767A1 (ru) 2021-04-13
SG11202011366SA (en) 2020-12-30
WO2019224096A1 (en) 2019-11-28
CA3100448A1 (en) 2019-11-28
CN112469719B (zh) 2024-01-23
HUE060654T2 (hu) 2023-04-28

Similar Documents

Publication Publication Date Title
IL277079A (en) Cartirin preparations and methods of use
EP3230234A4 (en) Nitrification inhibitor compositions and methods for preparing the same
EP3250035A4 (en) COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS
PL3797107T3 (pl) Heteroskondensowane związki pirydonów oraz ich zastosowanie jako inhibitory idh
EP3826721C0 (en) NAPHTHYRIDINE COMPOUNDS AND USES THEREOF
ZA201704300B (en) Nitrification inhibitor compositions and methods for preparing the same
IL280809B (en) New preparations, their use and methods of their creation
EP3223820A4 (en) C5-c6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use
IL284514A (en) Halo-allylamine compounds and their use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
HUE051898T2 (hu) Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
EP3241844A4 (en) Antibody against neuropilin 1 and use thereof
EP3724194C0 (en) SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
IL277749A (en) Palladianolide compounds and their use
EP3263133B8 (en) Pyridinone compound and use thereof
EP3191447A4 (en) S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
EP3194396A4 (en) Diazine-fused amidine compounds as bace inhibitors, compositions, and their use
GB201614961D0 (en) Compounds and compositions for use
PL3268356T3 (pl) Związki heterocykliczne i sposoby ich stosowania
EP4051270A4 (en) 4-AMINO-IMODAZOCINOLINE COMPOUNDS AND USES THEREOF
FI3724196T3 (fi) Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
GB201813311D0 (en) Novel compounds and their use
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors